Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen

BackgroundThe triplet combination of chemotherapy (docetaxel), androgen receptor pathway inhibitors (ARPI), and androgen deprivation therapy has recently become a recommended approach to treat metastatic castration-sensitive prostate cancer (mCSPC). This study aimed to compare the incremental time a...

Descripción completa

Detalles Bibliográficos

Autores principales:	Daniel Sentana-Lledo, Arjun Gupta, Carmine Rossi, Sabree Burbage, Jill Korsiak, Lilian Diaz, Gordon Wong, Dominic Pilon, Ibrahim Khilfeh, Alicia K. Morgans
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2025-09-01
Colección:	Frontiers in Oncology
Materias:	androgen receptor antagonists chemotherapy hormone receptor agonists mCSPC prostate neoplasms time burden
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1650378/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!